OUS Commercialization Activities Sample Clauses

OUS Commercialization Activities. Lilly shall have responsibility for Commercialization activities outside the U.S., including development, approval and implementation of the Commercialization Plan as it relates to the Territory outside the U.S. (the “OUS Commercialization Plan”). Amylin will have advisory input into the OUS Commercialization Plan, but all decisions as to the content of the OUS Commercialization Plan, the OUS Commercialization Budget, and the Commercialization activities to be conducted outside the U.S. shall be made by Lilly, provided, however, that Lilly shall comply with its obligations under the Agreement as modified by this Amendment. Notwithstanding the foregoing, any portion of the Commercialization Plan specifically relating to Non-BID Commercialization Trial Costs shall be subject to the approval pursuant to the Binding Budget process of the Agreement. Nothing in this Amendment shall be construed as modifying the provisions in the Agreement related to Manufacturing or to selection of trademarks, or any other rights that are not specifically changed by this Amendment, all of which shall continue in effect, or any other right of review, approval or participation of Amylin under the Agreement except to the extent specifically provided in this Amendment. The terms of the Clinical Research Quality Agreement between the Parties dated May 14, 2004 shall continue in effect. Through the GDCC, Amylin and Lilly agree to modify the roles and responsibilities guidance for activities outside of the U.S. such that Amylin retains its current participation in the Lilly Brand Council I and II processes. In addition, GDCC will modify the OUS roles and responsibilities to maintain Amylin’s current ability to review and provide input into the Affiliate Brand Plans for the Major OUS Markets. Lilly and Amylin anticipate the OUS roles and responsibilities document will be updated to include the following topics. · Addition of Amylin Medical and Team management into the Brand Council I and II process. ***CONFIDENTIAL TREATMENT REQUESTED · Clarification of Amylin’s ability to review and provide input on OUS Major Market affiliate plans versus review and input of Non-Major OUS Market affiliate plans. · Clarification of a Brand Council III alliance process that provides Amylin representatives the appropriate venue and access to personnel to review and provide input on OUS Major Market affiliate plans.